Formosa Pharmaceuticals News
Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia
February 15th, 2023 The collaboration will combine Formosa’s proprietary APNT™ nanoparticle formulation platform with Eyenovia’s Optejet® dispensing technology for the development of new ophthalmic therapies …
Formosa Pharmaceuticals Announce a Summary of Integrated Clinical Results for APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery
January 31st, 2023 TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) report a summary of integrated clinical results for APP13007, a novel ophthalmic nanosuspension formulation of …
Formosa Pharmaceuticals, completes successful pre-NDA Meeting with the US FDA and plans for NDA submission of APP13007
November 8th, 2022 Taipei, Taiwan – Formosa Pharmaceuticals, Inc. (TWO.6838) and development partner, AimMax Therapeutics, Inc. (US), announced the completion of a pre-NDA meeting with …
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery.
TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-302, the second of the two pivotal …
Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (TWO.6838) and Aimmax Therapeutics, Inc. (United States) announced that results from a Phase 2 clinical study of APP13007 (Clobetasol …
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery
TAIPEI, May 12, 2022 /PRNewswire/ — Formosa Pharmaceuticals, Inc. (TWO.6838) and AimMax Therapeutics, Inc. (United States) report successful top-line results from CPN-301, the first of …
